# Eton Pharmaceuticals (ETON): value investors who own it

1 value investor held Eton Pharmaceuticals in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $1.6m | Added +51% | 2 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-06 | Krempa David | Chief Business Officer | Sold | 4166 | $229k |
| 2026-08-28 | MAIER PAUL V | Director | Sold | 36387 | $2.1m |
| 2026-08-28 | MAIER PAUL V | Director | Sold | 13485 | $812k |
| 2026-08-28 | MAIER PAUL V | Director | Sold | 128 | $8k |
| 2026-08-24 | Krempa David | Chief Business Officer | Sold | 25000 | $1.6m |
| 2026-08-20 | BRYNJELSEN SEAN | President & CEO | Sold | 47307 | $2.8m |
| 2026-08-20 | BRYNJELSEN SEAN | President & CEO | Sold | 36373 | $2.2m |
| 2026-08-20 | BRYNJELSEN SEAN | President & CEO | Sold | 7342 | $456k |
| 2026-08-19 | BRYNJELSEN SEAN | President & CEO | Sold | 8978 | $562k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/eton). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.